Back to results
US 9,434,610 B2Granted
HPMA—docetaxel conjugates and uses therefore
AssigneesRexahn Pharmaceuticals, Inc., University of Maryland, Baltimore
InventorsYoung B. Lee, Deog J. Kim, Chang H. Ahn, Anjan Nan, Hamidreza Ghandehari, Abhijit Ray
Life of this patent
Estimating the term…
Abstract
Disclosed are water-soluble compositions of gemcitabine and docetaxel formed by conjugating the gemcitabine or docetaxel to a water-soluble polymer such as N-2-hydroxypropyl methacrylamide (HPMA). Also disclosed are methods of using the compositions of the invention for the treatment of cancer.
Claims19
A compound comprising:
- a carrier molecule,
- a linker molecule covalently attached to the carrier molecule,
- a targeting ligand covalently attached to the carrier molecule, optionally through a second linker, and
- an anticancer agent covalently attached to the linker molecule, wherein the anticancer agent is docetaxel, and wherein the carrier molecule comprises poly(N-2-hydroxypropylmethacrylamide) (poly-HPMA).
1 more element
A compound comprising:
- a carrier molecule,
- an anticancer agent covalently attached to the carrier molecule, optionally through a linker molecule, and
- a targeting ligand covalently attached to the carrier molecule, optionally through a second linker molecule, wherein the targeting ligand is selected from the group consisting of RGDfK, EPPT1, and folate, wherein the anticancer agent is docetaxel, and wherein the carrier molecule comprises poly(N-2-hydroxypropylmethacrylamide) (poly-HPMA).
Dependencies are inferred from the claim text.